Other BriefingsChina to Grant Market and Data Exclusivity for Innovative Drugs for the First Time
China’s new drug exclusivity regulations mark an important development for drug developers, as revised Drug Administration Law implementation rules introduce market exclusivity for pediatric and orphan drugs and data exclusivity protections for innovative chemical entities. The reforms, effective May 15, 2026, also introduce accelerated approval pathways in order to encourage the development of innovative and under-researched drugs. The new measures aim to strengthen commercial viability for drug developers and close the regulatory protection gap between China and mature pharmaceutical markets.
On January 27, 2026, the State Council released the revised Regulations for the Implementation of the Drug Administration Law of the People’s Republic of China (hereinafter, the “revised regulations”), marking the first comprehensive revision of the regulations since they came into force in 2002. Among other changes, the revised regulations introduce market exclusivity and data exclusivity provisions for innovative drugs, and formally enshrine a framework of accelerated regulatory pathways for drugs with significant clinical value at the administrative level.
The revised regulations provide additional market protections to drug developers by granting market and data exclusivity to high-cost but important drug categories, helping to protect innovations against copycat competitors while encouraging the development of innovative and under-researched drugs.
The revised regulations will come into effect on May 15, 2026.
Market exclusivity
The revised regulations grant market exclusivity to pediatric and orphan drugs for the first time. The market exclusivity periods are as follows:
- Up to two years for new types of pediatric medicines, pediatric medicines that use new delivery methods or specifications, and medications with expanded indications for children that meet certain conditions; and
- Up to seven years for medicines for orphan drugs that meet certain conditions, provided that the market license holder commits to guaranteeing the supply of the medicine. The market exclusivity period will be terminated if the market license holder fails to fulfill its supply obligations.
The specific conditions and methods for granting the market exclusivity periods, which will be formulated by the State Council’s drug regulatory authorities, have yet to be released at the time of writing.
China maintains lists of orphan diseases, with 207 different orphan diseases currently included across two catalogs. The first, from 2018, covers 121 diseases, while the second, released in 2023, added a further 86 diseases. Different regions of China also maintain their own local catalogs of rare diseases, such as the list of main orphan diseases released by Shanghai in 2025, which covers 278 diseases.
The limited patient populations for pediatric and orphan drugs have historically made it difficult for developers to recover their investments, thus disincentivizing the development of these important but less lucrative treatments. The introduction of market exclusivity periods for these drug categories can help to guarantee a protected revenue window for developers, which could make them more attractive to investors and financially viable for pharmaceutical companies.
Data exclusivity
In addition to the market exclusivity periods, the revised regulations now include provisions protecting undisclosed test data and other data obtained independently by a market license holder for drugs containing novel chemical components, as well as other eligible drugs.
Article 22 of the revised regulations stipulates that “no one may improperly use such undisclosed test data and other data for commercial purposes” and stipulates a protection period of up to six years from the date of the drug registration for this data.
During this period, applications for drug registration from other entities that use this data without the license holder’s consent will not be approved. This does not apply to data that has been independently obtained by the applicant.
The drug regulator may also not disclose this data, except in the following circumstances:
- Where public interest necessitates it; or
- Where measures have been taken to ensure that the data will not be improperly used for commercial purposes.
The specific protection measures for the data will be formulated by the State Council’s drug regulatory authorities and have yet to be released at the time of writing.
Along with the market exclusivity periods, the data exclusivity periods provide protection for developers that goes beyond patents by addressing the risk that competitors could exploit a developer’s proprietary clinical data to support their own registration applications. By prohibiting such use for up to six years from registration, the provision ensures that developers of drugs containing novel chemical components or formulations can recoup their data generation investment independently of their patents.
Expedited approval for clinically valuable drug research
The revised regulations introduce a fast track for the approval of certain types of drugs to facilitate market entry.
Article 15 of the revised regulations states that, in an effort to support clinically valuable drug research and innovation, the State Council’s drug regulatory authorities “may apply procedures such as the Breakthrough Therapy Designation, conditional approval, priority review and approval, and special approval to eligible drug registration applications to expedite market authorization”.
Separately, the State Council’s drug regulatory authorities will establish and improve review and approval, inspection and testing, and standards management systems to make it more compatible with the characteristics of traditional Chinese medicine.
Under China’s Drug Administration Law, the State Council’s drug regulatory authorities are required to organize pharmaceutical, medical, and other technical personnel to review drug registration applications, who are then tasked with examining the drug’s safety, efficacy, and quality controllability, as well as the applicant’s capabilities in quality management, risk control, and liability compensation.
Throughout this process, the drug regulatory authorities also have to concurrently review and approve chemical raw materials, review related excipients (excipients and additives used in the production of pharmaceuticals and the preparation of prescriptions), packaging materials, and containers that make direct contact with the drug, and approve the drug’s quality standards, manufacturing processes, labels, and instructions.
This is a cumbersome procedure that can take up to 200 days, as stipulated under the Drug Registration Management Measures, although expedited processes exist for certain types of drugs and in certain scenarios.
Incentive and support mechanisms for the development of innovative drugs
China has introduced a variety of incentive programs aimed at encouraging the development of innovative therapies and under-invested drugs.
One such program is the Breakthrough Therapy Designation (BTD) program mentioned above. Introduced in pilot form in 2020, this program provides additional resources and guidance to support the development of improved new drugs used to prevent or treat diseases that seriously endanger life or severely affect quality of life. There must also currently be no effective prevention or treatment methods for the diseases, or alternatively, there must be sufficient evidence to show a significant clinical advantage compared to existing treatments. For drugs included in the BTD program, the Center for Drug Evaluation (CDE) will prioritize resource allocation and communication in order to strengthen guidance and promote drug development.
Drug developers can also benefit from the range of tax incentives provided to research institutions in China, such as the R&D super deduction policy, in which eligible companies can deduct a total of 200 percent of their R&D expenses before tax, resulting in lower corporate income tax payable for a given tax year.
Another significant program to enhance the commercial viability of innovative drugs is the expansion of the list of drugs that are covered by the country’s national basic medical insurance, maternity insurance, and work injury insurance to include more innovative drugs.
In December 2025, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security (MOHRSS) released the 2025 edition of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue (the “national basic insurance catalog”). The 2025 edition added 114 new drugs, including 50 Class 1 innovative drugs, to the catalog of drugs covered or partially covered by the basic national health insurance, bringing the total to 3,253. According to the NHSA, the expansion of this catalog, which came into effect on January 1, 2026, will significantly improve access to drugs for cancer, chronic disease, mental illness, and rare diseases, as well as pediatric medications.
Inclusion in the coverage of national health insurance is in itself a huge boon to drug developers, instantly providing a vast possible patient base for drugs that would otherwise be too expensive for many patients to access. In 2025, 1.33 billion people in China participated in the country’s basic health insurance, according to the NHSA.
The NHSA also released the Commercial Health Insurance Innovative Drug Catalog (2025) as a supplement to the national basic insurance catalog. The country’s first such catalog, it covers 19 high-value innovative drugs, including orphan and pediatric medications, that are too expensive for the national insurance system, and is designed to encourage commercial insurers to extend coverage to these drugs. This will help lower barriers to patient access while expanding the possible patient base for developers, improving the commercial viability of and potentially incentivizing further research and development in these areas.
Implications for foreign pharmaceutical companies and investors
For foreign pharmaceutical companies and life sciences investors, the revised regulations mark a meaningful shift in China’s innovation policy toward stronger regulatory protection and commercial predictability, particularly for high-value, high-risk drug development.
Enhanced commercial viability for foreign innovators
The introduction of market exclusivity and data exclusivity narrows a longstanding gap between China and mature pharmaceutical markets such as the United States, the EU, and Japan. For multinational drug developers, these protections reduce exposure to early generic or follow-on competition and improve the risk-return profile of launching innovative drugs in China, especially in pediatric and orphan indications where patient populations are limited and development costs are high.
This is particularly relevant for foreign companies that previously relied primarily on patent protection, which can be vulnerable in practice due to disclosure requirements, enforcement challenges, or timing mismatches between patent life and market approval. Regulatory exclusivity operates independently of patents, offering an additional layer of protection.
Greater incentives for early China market entry
By anchoring data exclusivity to the date of drug registration, the revised regulations increase the strategic value of early China filings, including for drugs already approved overseas. Foreign developers may be more inclined to pursue parallel or near-parallel global development strategies, rather than deferring China entry until after commercialization in other markets.
The availability of expedited approval pathways, such as breakthrough therapy designation, conditional approval, and priority review, further supports this trend, especially for therapies addressing unmet clinical needs. For global companies, this may reduce time-to-market gaps between China and other major jurisdictions and raise China’s importance in global launch planning.
Supply and compliance considerations for orphan drugs
For orphan drugs, the linkage between market exclusivity and guaranteed supply obligations introduces both opportunity and compliance risk for foreign market license holders. While the potential seven-year exclusivity period is commercially attractive, failure to meet supply commitments may lead to early termination of exclusivity.
Foreign companies will therefore need to carefully assess local manufacturing, import logistics, pricing, and distribution arrangements, as well as coordination with domestic partners, to ensure continuity of supply throughout the exclusivity period.
Interaction with pricing and reimbursement policy
The exclusivity framework should be assessed in conjunction with China’s national and commercial health insurance mechanisms. While inclusion in public reimbursement catalogs can significantly expand patient access, it often entails substantial price negotiations.
For foreign stakeholders, the revised regulations reinforce the importance of integrated China market strategies that align regulatory exclusivity planning with reimbursement timing, pricing strategy, and lifecycle management. Exclusivity may create a protected window, but commercial outcomes will still depend heavily on insurance coverage decisions.
Signals to foreign investors and licensors
From an investment and licensing perspective, the reforms send a positive signal on China’s policy direction. Stronger regulatory data protection and clearer exclusivity mechanisms can enhance the valuation of China-focused drug assets, support cross-border licensing deals, and reduce uncertainty in M&A due diligence.
Foreign investors may view the revised regulations as part of a broader effort to position China as a destination for original drug innovation, rather than solely a manufacturing or secondary commercialization market.
About Us China Briefing is one of five regional Asia Briefing publications. It is supported by Dezan Shira & Associates, a pan-Asia, multi-disciplinary professional services firm that assists foreign investors throughout Asia, including through offices in Beijing, Tianjin, Dalian, Qingdao, Shanghai, Hangzhou, Ningbo, Suzhou, Guangzhou, Haikou, Zhongshan, Shenzhen, and Hong Kong in China. Dezan Shira & Associates also maintains offices or has alliance partners assisting foreign investors in Vietnam, Indonesia, Singapore, India, Malaysia, Mongolia, Dubai (UAE), Japan, South Korea, Nepal, The Philippines, Sri Lanka, Thailand, Italy, Germany, Bangladesh, Australia, United States, and United Kingdom and Ireland. For a complimentary subscription to China Briefing’s content products, please click here. For support with establishing a business in China or for assistance in analyzing and entering markets, please contact the firm at china@dezshira.com or visit our website at www.dezshira.com.
- Previous Article Trademark Registration in Hong Kong: Strategic Considerations for International Businesses
- Next Article
